United Therapeutics/UTHR

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About United Therapeutics

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

Ticker

UTHR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Silver Spring, United States

Employees

1,168

UTHR Metrics

BasicAdvanced
$14B
Market cap
15.01
P/E ratio
$21.12
EPS
0.49
Beta
-
Dividend rate
$14B
0.49
3.775
3.503
3.747
11.24
21.39%
12.24%
20.08%
15.01
5.96
2.65
2.71
19.79
26.09%
41.95%
18.38%
33.01%

What the Analysts think about UTHR

Analyst Ratings

Majority rating from 16 analysts.
Buy

UTHR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
45.24% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$678M
10.25%
Net income
$307M
41.23%
Profit margin
45.24%
28.12%

UTHR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 9.18%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
$5.24
$5.38
$4.36
$6.17
-
Expected
$4.51
$5.04
$4.19
$5.65
$6.24
Surprise
16.30%
6.69%
4.16%
9.18%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for United Therapeutics stock?

United Therapeutics (UTHR) has a market cap of $14B as of July 03, 2024.

What is the P/E ratio for United Therapeutics stock?

The price to earnings (P/E) ratio for United Therapeutics (UTHR) stock is 15.01 as of July 03, 2024.

Does United Therapeutics stock pay dividends?

No, United Therapeutics (UTHR) stock does not pay dividends to its shareholders as of July 03, 2024.

When is the next United Therapeutics dividend payment date?

United Therapeutics (UTHR) stock does not pay dividends to its shareholders.

What is the beta indicator for United Therapeutics?

United Therapeutics (UTHR) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell United Therapeutics stock

Buy or sell United Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing